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A B S T R A C T
Background: Production of N-terminal pro-brain natriuretic peptide (NT) and BNP is equimolar.
Although NT clearance occurs only in the kidneys, BNP clearance occurs in the kidneys and other
organs. This study tested the hypothesis that NT/BNP ratio in children may be independently related
to cystatin C (CysC), a glomerular ﬁltration rate marker, when diastolic function and age/body size are
taken into consideration.
Methods: The study included 430 children (5.3  4.9 years) with heart disease who had undergone cardiac
catheterization and simultaneous BNP, NT, and CysC measurements. Pulmonary capillary wedge pressure
(PCWP) was used as a ventricular diastolic stretch marker. Variables showing skewed distribution were
transformed into a common logarithm.
Results: Univariate regression revealed that log NT/BNP was affected by PCWP (r = 0.12) and log CysC
(r = 0.57). When age and the log of body surface area (BSA) were added to the stepwise regression, age
was not adopted because of multicollinearity to log BSA, but PCWP (b = 0.10), log CysC (b = 0.22), and
log BSA (b = 0.66) were independent factors of log NT/BNP.
Conclusions: Renal dysfunction independently increased NT/BNP, whereas high BSA decreased it and is
the greatest determinant of NT/BNP. The observation that high PCWP decreased NT/BNP may suggest
that worsening heart failure slows BNP clearance from other organs, a compensatory pathway of heart
failure. These factors need to be considered when assessing BNP and NT.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Brain natriuretic peptide (BNP) is a hormone secreted by the
ventricular myocardium during increased wall stress caused by
excessive volume or pressure loading of the heart [1]. Plasma BNP
concentrations are elevated in patients with congestive heart
failure (HF) [2] and reﬂect the severity of HF and diastolic stretch
[3]. The plasma BNP concentration is useful in predicting
mortality and hospital readmission [4] in many etiologies of HF.* Corresponding author at: Staff Ofﬁce Building 110, Pediatrics, Saitama Medical
Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama 350-8550,
Japan. Tel.: +81 49 228 3550; fax: +81 49 226 1424.
E-mail address: masutani@saitama-med.ac.jp (S. Masutani).
http://dx.doi.org/10.1016/j.jjcc.2014.11.002
0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsN-terminal pro-BNP (NT) [5–7] is another recent option for
such use. NT can be measured from the serum, whereas BNP
measurement requires plasma. NT is much more stable than BNP in
blood samples at room temperature. Thus, NT use has been greatly
increasing, and there is a growing body of evidence about the
usefulness of NT. Moreover, the required amount of serum for
NT measurement is only about 20 mL, which may promote further
use in neonatal and pediatric settings. NT also correlates with
BNP in pediatric patients [8,9]. The ratio of NT to BNP (NT/BNP)
increases with renal impairment [10] and decreases with
increasing age [11].
However, the relationship between NT and BNP levels appears
more complicated, and the factors contributing to it are not yet
established. Because of the equimolar production of NT and BNP,
NT/BNP depends on the clearance rate of each hormone. NT reserved.
Table 1
Diagnoses of included patients.
Disease (N = 430) Number of patients
Atrial septal defect 82
Single ventricle 55
Tetralogy of Fallot 41
Patent ductus arteriosus 31
Ventricular septal defect 29
Pulmonary atresia with/without other CHD 25
Transposition of great arteries 26
Double outlet right ventricle 19
Congenitally corrected transposition of great arteries 15
Coarctation of aorta 13
Hypoplastic left heart syndrome 12
Aortic stenosis 8




Total anomalous pulmonary venous connection 5
Hypoplastic left ventricle 4
Others 38
Total 430
CHD, congenital heart disease.
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[12]. In contrast, BNP clearance occurs in the kidneys, liver,
lungs, and vascular endothelium [1] via the clearance receptor
(natriuretic peptide receptor-C) and neutral endopeptidases
[13]. Thus, NT/BNP should be determined by the clearance rate
between the kidneys and other organs. If this relationship
becomes clear, each value of BNP or NT can be approximately
converted to the other.
The clearance balance of both hormones may be affected by
maturation-related and maturation-unrelated functional states of
the kidneys and other organs. HF by itself may affect the clearance
of both hormones. Thus, this study tested the hypothesis that
NT/BNP may be determined by cystatin C (CysC) [14–17], a
muscular mass-independent glomerular ﬁltration rate marker,
maturation, and severity of HF in children.
Methods
Patients
The study included 430 consecutive pediatric patients with
heart disease (age <20 years, 198 male and 232 female) who had
undergone cardiac catheterization and simultaneous measure-
ments of pulmonary capillary wedge pressure (PCWP), BNP, NT,
and CysC at Saitama Medical University International Medical
Center. Their ages ranged from 0.16 to 19.1 years [mean  standard
deviation (SD), 5.3  4.9 years; median, 3.3 years]. Patients under-
went diagnostic or interventional cardiac catheterization at Saitama
Medical University, with written informed parental consent obtained
for all the patients. This study was approved by the Institutional
Review Board of Saitama Medical University.
Measurements
PCWP was regularly measured during cardiac catheterization.
We used PCWP as a representative measure of diastolic function
and ventricular stretch. Systemic output (Qs) was calculated using
the Fick method and Qs index (QsI) was calculated as Qs/body
surface area (BSA). Blood sampling to determine CysC levels was
performed 1 day before cardiac catheterization as part of routine
blood testing. Blood samples of BNP and NT were withdrawn from
the inferior vena cava at the beginning of cardiac catheterization.
Measurements of BNP were performed using enzyme immunoas-
say, NT using electrochemiluminescence immunoassay, and CysC
using latex-enhanced turbidimetric immunoassay.
Statistical analysis
All data are presented as mean  SD, unless otherwise stated.
Variables showing skewed distribution were transformed into a
common logarithm before the correlation analysis. Pairwise compar-
isons were performed using the paired t-test. The correlation between
two variables was assessed using Pearson’s correlation coefﬁcient.
After univariate regression, to determine the independent variables
that correlate with BNP, NT, NT/BNP, stepwise multivariate linear
regression analysis was performed using the following variables:
gender, log BSA, log CysC, and PCWP. Subsequently, we performed
subgroup analysis to assess whether the difference between left- or
right-sided volume load may relate to log NT/BNP, and whether the
difference between pressure and volume load may affect NT/BNP.
Atrial septal defect (ASD) patients were used as a right-sided volume
overload group, and ventricular septal defect (VSD) and patent ductus
arteriosus (PDA) patients as a left-sided volume overload group.
Coarctation of the aorta (CoA) and aortic stenosis (AS) patients were
used as a left-sided pressure overload group. We compared log
NT/BNP values between right- and left-sided volume overload groups,and between left-sided pressure and volume overload groups.
Statistical signiﬁcance was assumed at an error level of 5%. Statistical
analyses were performed using JMP 8 (SAS, Cary, NC, USA).
Results
As summarized in Table 1, patients with various underlying
heart diseases (N = 430) were included in this study. The range and
distribution of each parameter are shown in Table 2.
Univariate regression
Table 3 summarizes the results of univariate regression. Gender
did not relate to log NT, log BNP, or log NT/BNP. In contrast, age,
body size (body weight, body height, and BSA), log CysC, and PCWP
signiﬁcantly correlated to log NT, log BNP, and log NT/BNP. Log
NT/BNP negatively correlated with age (r = 0.71, p < 0.0001), and
the relation was a convex downward curve (Fig. 1a). There was
strong negative linear correlation between log NT/BNP and log BSA
(r = 0.79, p < 0.0001) (Fig. 1b). Log NT/BNP positively correlated
with log CysC (r = 0.57, p < 0.0001) (Fig. 1c), and negatively
correlated with PCWP (r = 0.12, p < 0.05) (Fig. 1d). BNP was
much less inﬂuenced by age, BSA, and CysC compared with NT,
as indicated by a smaller correlation coefﬁcient in Table 3.
Multivariate regression
Table 4 summarizes the results of multivariate regression.
When age, log BSA, log CysC, and PCWP were added as indepen-
dent variables into stepwise regression to correlate to log NT/BNP,
age was not adopted because of multicollinearity to log BSA, but
PCWP (b = 0.10), log CysC (b = 0.22), and log BSA (b = 0.66)
were independent factors of log NT/BNP (Table 4). Not only body
size and renal function, but also PCWP, independently related
to the log NT/BNP. Higher PCWP negatively affected log NT/BNP.
Log NT/BNP can be approximated with the regression by
0.66  log BSA  0.10  PCWP + 0.22  log CysC + 0.86. There was
signiﬁcant correlation between the measured and estimated log
NT/BNP calculated by this approximation [RMSE = 0.18, R2 (coefﬁcient
of determination) = 0.66, p < 0.0001]. Residual plot showed no
tendency between residuals and estimated values.
Fig. 2 shows the results of subgroup analysis assessing whether
the difference between pressure or volume load may relate to
Table 2
Distribution of each parameter (N = 430).
Mean  SD Range Median (interquartile range)
Age (years) 5.35  4.93 0.16 to 19.1 3.31 (1.65–7.21)
Male (%) 197 (45.9%)
Body weight (kg) 19.0  15.1 3.8 to 86.0 13.0 (9.2–21.5)
Body height (mL/m2) 101  31 49 to 181 91.8 (77–119.3)
Body surface area (m2) 0.71  0.39 0.22 to 2.0 0.71 (0.43–0.85)
CysC (mg/L) 0.95  0.22 0.59 to 1.88 0.91 (0.79–1.07)
Qs index (L/min/m2) 3.65  1.07 1.49 to 7.84 3.58 (2.91–4.31)
Qp/Qs 1.36  0.74 0.42 to 4.5 1.0 (0.96–1.62)
PCWP (mmHg) 9.73  3.2 2 to 24 9.25 (7.5–12)
NT-pro BNP (pg/mL) 428  991 7 to 14600 186 (78–418)
log NT-pro BNP 2.27  0.53 0.85 to 4.16 2.27 (1.90–2.62)
BNP (pg/mL) 43.5  142 4 to 2655 20 (10.6–35.1)
log BNP 1.33  0.43 0.60 to 3.42 1.30 (1.02–1.54)
NT/BNP 11.2  10.0 0.76 to 97.3 8.62 (5.37–8.62)
log NT/BNP 0.94  0.31 0.12 to 1.99 0.94 (0.73–1.10)
Data are presented as mean  standard deviation, median (interquartile range), or frequency (within-group percentage).
CysC, cystatin C; Qs, systemic output; Qp, pulmonary output; PCWP, pulmonary capillary wedge pressure; NT, N-terminal; BNP, brain natriuretic peptide.
Table 3
Univariate analysis of NT-pro BNP, BNP, and NT/BNP.
log NT-pro BNP log BNP log NT/BNP
r p r p r p
Age (years) 0.61 <0.0001 0.25 <0.0001 0.71 <0.0001
Gender 0.65 0.89 0.29
log Body weight (kg) 0.72 <0.0001 0.34 <0.0001 0.78 <0.0001
log Body height (mL/m2) 0.69 <0.0001 0.30 <0.0001 0.79 <0.0001
log Body surface area (m2) 0.71 <0.0001 0.32 <0.001 0.79 <0.0001
log CysC (mg/L) 0.46 <0.0001 0.16 0.001 0.57 <0.0001
PCWP (mmHg) 0.23 <0.0001 0.38 <0.0001 0.12 0.011
CysC, cystatin C; PCWP, pulmonary capillary wedge pressure; NT, N-terminal; BNP, brain natriuretic peptide.
Fig. 1. Correlation between logarithm of the ratio between N-terminal pro-BNP and BNP (log NT/BNP) and other factors. (a) Log NT/BNP negatively correlates with age; the
relation is a convex downward curve. (b) There is a strong negative linear correlation between log NT/BNP and log BSA. (c) Log NT/BNP positively correlates with log CysC. (d)
Log NT/BNP negatively correlates with PCWP. BNP, brain natriuretic peptide; BSA, body surface area; CysC, cystatin C; NT, N-terminal pro-BNP; PCWP, pulmonary capillary
wedge pressure.
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Table 4
Multivariate regression analysis of NT-pro BNP, BNP, and NT/BNP.
log NT-pro BNP log BNP log NT/BNP
b p b p b p
Gender 0.60 0.87 0.48
log Body surface area (m2) 0.73 <0.0001 0.41 <0.0001 0.66 <0.0001
log CysC (mg/L) 0.38 0.12 0.021 0.22 <0.0001
PCWP (mmHg) 0.28 <0.0001 0.42 <0.0001 0.10 0.0005
CysC, cystatin C; PCWP, pulmonary capillary wedge pressure; NT, N-terminal; BNP, brain natriuretic peptide.
Fig. 2. Subgroup analysis to assess whether different types of heart disease relate to log NT/BNP. (a) Left ventricular pressure load vs. volume load. Log NT/BNP was not
signiﬁcantly affected (p = 0.76) by the differences between the AS/CoA (n = 21) and VSD/PDA (n = 60) groups. (b) Left- vs. right-sided volume load. Multivariate
comparison showed that log NT/BNP in the ASD (n = 82) was slightly (b = 0.13) but signiﬁcantly (p < 0.05) higher than that in the VSD/PDA (n = 60) group when
log BSA was taken into consideration. This signiﬁcance was preserved (p < 0.05) when we matched the body size between the two groups by only including data from
VSD/PDA patients with log BSA >0.4 (n = 41). However, when we added Qp/Qs into the multivariate analysis, the difference between the ASD and VSD/PDA groups was
no longer signiﬁcant, but Qp/Qs was shown to be a signiﬁcant independent factor for log NT/BNP (p < 0.05, b = 0.16). AS, aortic stenosis; BNP, brain natriuretic
peptide; BSA, body surface area; CoA, coarctation of the aorta; NT, N-terminal pro-BNP; PDA, patent ductus arteriosus; Qp/Qs, pulmonary-to-systemic output ratio;
VSD, ventricular septal defect.
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right-sided volume load may relate to log NT/BNP. As shown
in Fig. 2a, log NT/BNP was not signiﬁcantly affected (p = 0.76)
by the differences between the AS/CoA (n = 21) and VSD/PDA
(n = 60) groups. Fig. 2b shows that log NT/BNP in ASD (n = 82)
was slightly (b = 0.13) but signiﬁcantly (p < 0.05) higher than
that in VSD/PDA (n = 60). This signiﬁcance was preserved
(p < 0.05) when we matched the body size between the two
groups by only including data from VSD/PDA patients with
log BSA >0.4 (n = 41). However, in this subgroup analysis, the
pulmonary-to-systemic output ratio (Qp/Qs) in ASD was signiﬁ-
cantly higher than that in VSD/PDA (2.2  0.8 vs. 1.4  0.4,
p < 0.0001). When we added Qp/Qs into the multivariate analysis,
the difference between the ASD and VSD/PDA groups was no longer
signiﬁcant, but Qp/Qs was found to be a signiﬁcant independent
factor for log NT/BNP (p < 0.05, b = 0.16).
Discussion
The major ﬁndings in this pediatric study regarding NT/BNP
were: (1) renal dysfunction increased NT/BNP levels, (2) high
BSA levels decreased NT/BNP as the greatest and powerful
determinant of NT/BNP (b = 0.66), and (3) high PCWP
decreased NT/BNP. This is the ﬁrst study, to our knowledge,
to reveal a detailed relationship between NT and BNP with body
size, renal function, and invasive diastolic measurements taken
into consideration. Simultaneous measurements of both hor-
mones may provide an insight into NT and BNP clearance in the
kidneys and other organs. Factors that affect the clearance of
both hormones need to be considered when assessing HF
severity using NT or BNP.Renal contribution
Renal dysfunction independently increased NT/BNP (Fig. 1c and
Tables 3 and 4). In adults, one of the most important factors
affecting the NT/BNP ratio is renal function [18]. NT/BNP ratio
increases exponentially with the stage of renal disease [10]. NT/
BNP ratios in a population of patients receiving long-term
hemodialysis were much higher than those found in patients
with end-stage renal disease not receiving dialysis [19]. Thus, the
result of our study in children, which used a sufﬁcient number of
patients with body size and diastolic function taken into account,
was consistent with those of aforementioned studies in adults
[10]. Renal dysfunction predominantly slowed the clearance of NT
relative to BNP and increased the NT/BNP ratio regardless of
whether this was a child or adult population.
Although observations that NT/BNP increases as renal function
decreases have been consistently reported in previous [10,18,20]
and current studies, mechanistic studies surprisingly demonstrated
that the kidney clears NT and BNP equally [13] in various subjects
[20–22]. Other possible mechanisms to explain the NT/BNP increase
in patients with renal dysfunction may be the relative NT increase by
saturable NT clearance [12], the relative BNP decrease by the
upregulation of type C natriuretic receptor [20], and the accumula-
tion of neutral endopeptidases [20,23]. These issues should be
pursued in future studies.
Body size vs. age
High BSA decreased NT/BNP and was the greatest and most
powerful determinant of NT/BNP (Fig. 1b and Tables 3 and 4). The
results of a previous pediatric study [11] and the current study
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childhood to adolescence. An age-dependent decrease of NT/BNP
can be partly explained by the maturation of renal function.
Our data also indicate the age-related decrease of CysC in patients
<2 years (data not shown). However, multivariate regression in
this study showed that body size was an independent greatest
factor to determine NT/BNP with renal function taken into
consideration. Importantly, the relationship between log NT/BNP
and log BSA was tighter than that between log NT/BNP and
age. These observations suggest that the proportion of the BNP
clearance in other organs relative to that in kidney may be larger
in smaller children in body-size related fashion.
HF
High PCWP decreased NT/BNP, indicating a relatively greater
increase of BNP relative to NT. Importantly, only BNP, but not NT,
has active anti-HF activities. Thus, the tendency to preserve BNP
concentration in HF should serve as a compensatory mechanism.
This effect was signiﬁcant but not as strong (b = 0.10) as other
factors. This BNP preservation may not be sufﬁcient in some
clinical HF situations in which exogenous BNP [24] or neutral
endopeptidase inhibitor [25] administration is particularly
effective.
Our observation suggests that worsening HF may relatively
slow BNP clearance from organs other than kidney. Although
‘‘clearance’’ receptor upregulation [26,27] and neutral endopepti-
dase activation [28,29] in HF may work to decrease BNP, once the
number of BNP receptors on the cell surface is maximized, they
may become saturated by BNP, reducing the overall clearance rate
for BNP [30]. However, the complete picture of HF effect on NT and
BNP clearance remains to be elucidated. Future studies that
examine the serial changes of two hormones and other factors
between baseline and acute exacerbation in severe HF would help
clarify the detailed effect of HF on the clearance of BNP and NT.
Levels of intact pro-BNP, a precursor of BNP and NT, are
also increased in HF [31]. Because present BNP immunoassays also
measure pro-BNP [31], this factor may partly explain the HF effect
on NT/BNP. This issue warrants future study.
In subgroup analysis (Fig. 2), the difference between pressure
and volume load did not relate to log NT/BNP. In this study, ASD
patients had higher Qp/Qs than VSD/PDA patients. The slightly
higher log NT/BNP in ASD than in VSD/PDA patients could be
explained by the Qp/Qs differences between the two groups. This
observation appears consistent with the theoretical prediction
that higher Qp/Qs should increase the log NT/BNP because BNP
clearance occurs also in the lungs, but NT clearance occurs only in
the kidney. The group difference was no more signiﬁcant when
Qp/Qs was added into the multivariate comparison. Thus, our
results did not indicate that the difference between right- and left-
sided volume load is an important determinant of log NT/BNP.
The current study provided novel ﬁndings of two points: the
effects of body size and potential HF compensation in natriuretic
hormone dynamics. Of note, BNP is much less inﬂuenced by age,
body size, or renal function, and much more inﬂuenced by PCWP
in comparison to NT (Table 4). In this regard, BNP [32] may be
appreciated as a more speciﬁc marker of HF, whereas NT with body
size correction may represent the entire cardiorenal system.
Current results underline the importance of standardizing NT by
age or body size and assessing renal function in the assessment of
both hormones in children. The reference value for NT in children
decreases with age [33]. For the evaluation of NT in children, use of
a Z-value of NT [33] is an important option for standardizing NT.
When the NT value is within the normal range, it indicates that the
cardiorenal system is functioning normally. In contrast, when
the NT value is above the normal range, assessment should beundertaken to determine whether cardiac dysfunction, renal
dysfunction, or both caused the high NT value. A high NT value
with body size or age correction should be assessed and followed
up with consideration of renal function and its trend. Measure-
ments of both hormone levels, if available, can be taken into
consideration to enable the qualitative assessment of both cardiac
and renal status.
Study limitations
Several issues should be considered in the interpretation of
our data. First, this study employed PCWP as a substitute for
ventricular stretch. PCWP is a stable measurement obtained by
right heart catheterization, whereas PCWP more directly provides
the effect of ventricular stretch than do echocardiographic indices.
Future studies using other diastolic parameters such as stiffness,
relaxation, and end-diastolic wall stress [3] are warranted to
further clarify the effect of HF on natriuretic peptide dynamics.
Second, in contrast to well-known BNP clearance mechanisms,
NT clearance remains to be elucidated. NT clearance occurs only
in the kidneys [1], but other clearance pathways other than the
kidneys [13] cannot be fully excluded. However, such pathways,
if they exist, would tend to suppress the NT/BNP increase in renal
dysfunction, but we observed that renal dysfunction independent-
ly and signiﬁcantly increased NT/BNP. Thus, the other clearance
pathways of NT except the kidneys would not change our results
or discussion.
In conclusion, renal dysfunction independently increased
NT/BNP, whereas high BSA decreased it, and was the greatest
determinant of NT/BNP in children with heart disease. Moreover,
high PCWP decreased NT/BNP, a potential compensatory pathway
of HF. These factors need to be considered in the assessment of
BNP and NT.
Funding
This study was partly supported by MEXT KAKENHI Grant
(no. 8025127 C.K.; no. 25461630 S.M.); grants from Nipro
Corporation, Kawano Memorial Foundation (no. 10-3, and 22-1),
and Tenshindo Medical Institution; and an internal grant from
Saitama Medical University.
Conﬂict of interest
The authors declare that there is no conﬂict of interest.
Acknowledgments
The abstract for this study was presented at the American Heart
Association Meeting (November 2013, Dallas, TX, USA).
We thank our university colleagues who performed the
catheterization studies.
References
[1] Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K,
Yoshimasa T, Nakao K. Rapid transcriptional activation and early mRNA
turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence
for brain natriuretic peptide as an ‘‘emergency’’ cardiac hormone against
ventricular overload. J Clin Invest 1995;96:1280–7.
[2] Masutani S, Taketazu M, Mihara C, Mimura Y, Ishido H, Matsunaga T,
Kobayashi T, Senzaki H. Usefulness of early diastolic mitral annular velocity
to predict plasma levels of brain natriuretic peptide and transient heart
failure development after device closure of atrial septal defect. Am J Cardiol
2009;104:1732–6.
[3] Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, Goto Y, Nonogi H. B-
type natriuretic peptide strongly reﬂects diastolic wall stress in patients with
chronic heart failure: comparison between systolic and diastolic heart failure.
J Am Coll Cardiol 2006;47:742–8.
C. Kurishima et al. / Journal of Cardiology 66 (2015) 175–180180[4] Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF,
Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillie`re Y. Plasma brain
natriuretic peptide-guided therapy to improve outcome in heart failure. The
STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733–9.
[5] Sugimoto M, Manabe H, Nakau K, Furuya A, Okushima K, Fujiyasu H, Kakuya F,
Goh K, Fujieda K, Kajino H. The role of N-terminal pro-B-type natriuretic
peptide in the diagnosis of congestive heart failure in children. Correlation
with the heart failure score and comparison with B-type natriuretic peptide.
Circ J 2010;74:998–1005.
[6] Troughton RW, Frampton CM, Yandle TG, Espine EA, Nicholls MG, Richards AM.
Treatment of heart failure guided by plasma aminoterminal brain natriuretic
peptide (N-BNP) concentrations. Lancet 2000;355:1126–30.
[7] Sato Y. Diagnostic and prognostic property of NT-proBNP in patients with renal
dysfunction. J Cardiol 2013;61:446–7.
[8] Price JF, Thomas AK, Grenier M, Eidem BW, O’Brian Smith E, Denﬁeld SW,
Towbin JA, Dreyer WJ. B-type natriuretic peptide predicts adverse cardiovas-
cular events in pediatric outpatients with chronic left ventricular systolic
dysfunction. Circulation 2006;114:1063–9.
[9] Kadar K, Nagy E, Gal K, Oprea V, Hartyanszky I, Gyarmati G, Toth A, Sikos Z.
Utility of B-type natriuretic peptide in children. Orv Hetil 2007;148:265–70.
[10] Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH. The effect of renal
dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol 2010;133:
14–23.
[11] Koch AM, Rauh M, Zink S, Singer H. Decreasing ratio of plasma N-terminal pro-
B-type natriuretic peptide and B-type natriuretic peptide according to age.
Acta Paediatr 2006;95:805–9.
[12] Palmer SC, Richards AM. Does renal clearance differ between the B-type
natriuretic peptides (BNP versus NT-proBNP)? J Am Coll Cardiol 2009;53:
891–2.
[13] Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi Jr JL. Biology of the
natriuretic peptides. Am J Cardiol 2008;101:3–8.
[14] Yana A, Masutani S, Kojima T, Saiki H, Taketazu M, Tamura M, Senzaki H.
Usefulness of cystatin C in the postoperative management of pediatric patients
with congenital heart disease. Circ J 2013;77:667–72.
[15] Stickle D, Cole B, Hock K, Hruska KA, Scott MG. Correlation of plasma con-
centrations of cystatin C and creatinine to inulin clearance in a pediatric
population. Clin Chem 1998;44:1334–8.
[16] Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y,
Grifﬁths RE, Devarajan P. Serum cystatin C is an early predictive biomarker of
acute kidney injury after pediatric cardiopulmonary bypass. Clin J Am Soc
Nephrol 2010;5:1552–7.
[17] Uemura O, Ushijima K, Nagai T, Yamada T, Hayakawa H, Nabeta Y, Shinkai Y,
Koike K, Kuwabara M. Reference serum cystatin C levels in Japanese children.
Clin Exp Nephrol 2010;14:453–6.
[18] Kemperman H, van den Berg M, Kirkels H, de Jonge N. B-type natriuretic
peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure
supported by a left ventricular assist device. Clin Chem 2004;50:1670–2.
[19] Jacobs LH, Mingels AM, Wodzig WK, van Dieijen-Visser MP, Kooman JP. Renal
dysfunction, hemodialysis, and the NT-proBNP/BNP ratio. Am J Clin Pathol
2010;134:516–7.[20] van Kimmenade RR, Januzzi Jr JL, Bakker JA, Houben AJ, Rennenberg R, Kroon
AA, Crijns HJ, van Dieijen-Visser MP, de Leeuw PW, Pinto YM. Renal clearance
of B-type natriuretic peptide and amino terminal pro-B-type natriuretic
peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol
2009;53:884–90.
[21] Goetze JP, Jensen G, Moller S, Bendtsen F, Rehfeld JF, Henriksen JH. BNP and
N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest
2006;36:8–15.
[22] Schou M, Dalsgaard MK, Clemmesen O, Dawson EA, Yoshiga CC, Nielsen HB,
Gustafsson F, Hildebrandt PR, Secher NH. Kidneys extract BNP and NT-proBNP
in healthy young men. J Appl Physiol (1985) 2005;99:1676–80.
[23] Deschodt-Lanckman M, Michaux F, De Prez E, Abramowicz D, Vanherweghem
JL, Goldman M. Increased serum levels of endopeptidase 24.11 (‘enkephali-
nase’) in patients with end-stage renal failure. Life Sci 1989;45:133–41.
[24] Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD,
Wagoner LE, Givertz MM, Liang C-S, Neibaur M, Haught WH, LeJemtel TH.
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompen-
sated congestive heart failure. N Engl J Med 2000;343:246–53.
[25] Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx
G, Qian C, Block AJ. Comparison of vasopeptidase inhibitor, omapatrilat, and
lisinopril on exercise tolerance and morbidity in patients with heart failure:
IMPRESS randomised trial. Lancet 2000;356:615–20.
[26] Andreassi MG, Del Ry S, Palmieri C, Clerico A, Biagini A, Giannessi D. Up-
regulation of ‘clearance’ receptors in patients with chronic heart failure: a
possible explanation for the resistance to biological effects of cardiac natri-
uretic hormones. Eur J Heart Fail 2001;3:407–14.
[27] Kuhn M, Voss M, Mitko D, Stypmann J, Schmid C, Kawaguchi N, Grabellus F,
Baba HA. Left ventricular assist device support reverses altered cardiac ex-
pression and function of natriuretic peptides and receptors in end-stage heart
failure. Cardiovasc Res 2004;64:308–14.
[28] Fielitz J, Dendorfer A, Pregla R, Ehler E, Zurbrugg HR, Bartunek J, Hetzer R,
Regitz-Zagrosek V. Neutral endopeptidase is activated in cardiomyocytes in
human aortic valve stenosis and heart failure. Circulation 2002;105:286–9.
[29] Knecht M, Pagel I, Langenickel T, Philipp S, Scheuermann-Freestone M,
Willnow T, Bruemmer D, Graf K, Dietz R, Willenbrock R. Increased expression
of renal neutral endopeptidase in severe heart failure. Life Sci 2002;71:
2701–12.
[30] Kroll MH, Srisawasdi P. The clearance of BNP modeled using the NT-proBNP-
BNP relationship. Biosystems 2007;88:147–55.
[31] Nishikimi T, Okamoto H, Nakamura M, Ogawa N, Horii K, Nagata K, Nakagawa
Y, Kinoshita H, Yamada C, Nakao K, Minami T, Kuwabara Y, Kuwahara K,
Masuda I, Kangawa K, et al. Direct immunochemiluminescent assay for
proBNP and total BNP in human plasma proBNP and total BNP levels in normal
and heart failure. PLOS ONE 2013;8:e53233.
[32] Masutani S, Saiki H, Kurishima C, Ishido H, Tamura M, Senzaki H. Heart failure
with preserved ejection fraction in children. Circ J 2013;77:2375–82.
[33] Shiraishi M, Fuse S, Mori T, Doyama A, Honjyo S, Hoshino Y, Hoshino E,
Kawaguchi A, Kuroiwa Y, Hotsubo T. N-terminal pro-brain natriuretic peptide
as a useful diagnostic marker of acute Kawasaki disease in children. Circ J
2013;77:2097–101.
